Prospective Ovarian Cancer Cohort To Authenticate Stratification Of Prognosis In Ovarian Tumours (POCCA-SPOT)
Funder
National Health and Medical Research Council
Funding Amount
$993,580.00
Summary
Ovarian cancer has poor survival, with less than 40% of women surviving 5 years. There is a wide range of survival, but very few characteristics that indicate which patients will do well or poorly. We have developed a tumour test at diagnosis, that can predict prognosis at 5 years. In newly diagnosed cases, we will test tumours to predict prognosis and then determine the accuracy and assess patient acceptability. This study will lead to clinical use of the test and improve treatment decisions.
Cancers can spread to the lung causing fluid build-up and requires drainages in hospital that are painful and costly. Surgery is previously seen as the definitive option to stop fluid forming, but is invasive with complications. Indwelling pleural catheter (IPC) is a novel implanted device inside the chest that allows patients to drain fluid at home. AMPLE Trial-3 is the first multicenter randomized clinical trial to compare surgery vs IPC to provide fluid control and improve quality of life.
Whole-of-population CRISPR Point-of-care Testing For Congenital Cytomegalovirus To Prevent Hearing And Neurodevelopment Disabilities Through A Public Health Approach
Funder
National Health and Medical Research Council
Funding Amount
$2,058,920.00
Summary
Congenital cytomegalovirus infection (cCMV) is the major infective cause of deafness and brain disability, both of which are potentially reversible with early treatment. Currently, there is no screening at birth, and cCMV is diagnosed too late for treatment. Our team will test and validate CRISPR, a new and cheap technology, on 110,000+ newborns to detect cCMV. This will revolutionise how cCMV is detected, make treatment more accessible and pave way to lower rates of deafness and cerebral palsy.